{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:07:08Z","timestamp":1788941228261,"version":"build-2803163510"},"posted":{"date-parts":[[2026,8,27]]},"group-title":"In Review","reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,8,17]]},"abstract":"<title>Abstract<\/title>\n                <p>Purpose.\n To determine whether cerebrospinal fluid (CSF) \u03b1-synuclein seed amplification assay (SAA) positivity identifies a reproducible soluble amyloid-\u03b2 (A\u03b2) configuration and whether its dimensions carry distinct information about downstream pathology and neurodegeneration.\nMethods.\n In ADNI, 72 participants (13 SAA-positive [SAA+]) had same-day BACE1 activity, sAPP\u03b2, and mass-spectrometry A\u03b238\/A\u03b240\/A\u03b242. T captured common A\u03b238\/A\u03b240 variation and D42 A\u03b242 depletion relative to A\u03b238\/A\u03b240. A one-factor measurement-error model tested common-factor compatibility. The pattern was then tested in 560 participant-disjoint individuals (131 SAA+), with T and D42 reconstructed de novo, and related to amyloid PET, clinical change, whole-brain MRI, and tau PET.\nResults.\n In the proximal cohort, SAA\u2009+\u2009was associated with lower T (\u03b2=-0.549 SD, 95% CI -1.005 to -0.093), but this effect was compatible with the one-factor model (directional compatibility probability\u2009=\u20090.288). In the participant-disjoint cohort, SAA\u2009+\u2009was associated with lower T (\u03b2=-0.267 SD) and higher D42 (\u03b2\u2009=\u20090.206 SD); their direct contrast was \u2212\u20090.473 SD. Higher D42 was associated with subsequent amyloid burden, faster 0-2.5-year clinical worsening, greater whole-brain loss, and subsequent tau burden; lower T independently predicted faster whole-brain loss.\nConclusions.\n SAA positivity identifies a reproducible T-low\/D42-high soluble-A\u03b2 configuration. The preferential association of D42 with fibrillar amyloid, tau burden, and clinical worsening links the A\u03b242-selective component to the AD pathological cascade, while the overall pattern points to altered post-\u03b2-cleavage APP\/A\u03b2 handling.<\/p>","DOI":"10.21203\/rs.3.rs-10731083\/v1","type":"posted-content","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:59:06Z","timestamp":1787792346000},"source":"Crossref","is-referenced-by-count":0,"title":["CSF \u03b1-synuclein seed amplification assay positivity identifies a distinct soluble amyloid-\u03b2 profile linked to fibrillar amyloid burden and structural neurodegeneration"],"prefix":"10.21203","author":[{"given":"Norberto","family":"Rodriguez-Espinosa","sequence":"first","affiliation":[{"name":"Universidad de La Laguna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzheimer\u2019s Disease Neuroimaging","family":"Initiative","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Disease Neuroimaging Initiative"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e70347","DOI":"10.1002\/dad2.70347","article-title":"Atrophy signature for alpha-synuclein copathology in Alzheimer\u2019s disease","volume":"18","author":"Esteller-Gauxax D","year":"2026","unstructured":"Esteller-Gauxax D, Guill\u00e9n N, Falg\u00e0s N et al (2026) Atrophy signature for alpha-synuclein copathology in Alzheimer\u2019s disease. Alzheimers Dement (Amst) 18:e70347. https:\/\/doi.org\/10.1002\/dad2.70347","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13024-025-00822-3","article-title":"Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer\u2019s disease","volume":"20","author":"Franzmeier N","year":"2025","unstructured":"Franzmeier N, Roemer-Cassiano SN, Bernhardt AM et al (2025) Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer\u2019s disease. Mol Neurodegener 20:31. https:\/\/doi.org\/10.1186\/s13024-025-00822-3","journal-title":"Mol Neurodegener"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack CR","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20:5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze S","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N et al (2016) CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 3:154\u2013165. https:\/\/doi.org\/10.1002\/acn3.274","journal-title":"Ann Clin Transl Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk WE","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC et al (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11:1\u201315e4. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003","journal-title":"Alzheimers Dement"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JAD-132489","article-title":"Qualification of a surrogate matrix-based absolute quantification method for amyloid-\u03b242 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry","volume":"41","author":"Korecka M","year":"2014","unstructured":"Korecka M, Waligorska T, Figurski M et al (2014) Qualification of a surrogate matrix-based absolute quantification method for amyloid-\u03b242 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis 41:441\u2013451. https:\/\/doi.org\/10.3233\/JAD-132489","journal-title":"J Alzheimers Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/clinchem\/hvaa012","article-title":"Analytical and clinical performance of amyloid-beta peptides measurements in CSF of ADNIGO\/2 participants by an LC-MS\/MS reference method","volume":"66","author":"Korecka M","year":"2020","unstructured":"Korecka M, Figurski MJ, Landau SM et al (2020) Analytical and clinical performance of amyloid-beta peptides measurements in CSF of ADNIGO\/2 participants by an LC-MS\/MS reference method. Clin Chem 66:587\u2013597. https:\/\/doi.org\/10.1093\/clinchem\/hvaa012","journal-title":"Clin Chem"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ab.2011.08.010","article-title":"Quantitation of amyloid beta peptides A\u03b2(1\u201338), A\u03b2(1\u201340), and A\u03b2(1\u201342) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry","volume":"419","author":"Lame ME","year":"2011","unstructured":"Lame ME, Chambers EE, Blatnik M (2011) Quantitation of amyloid beta peptides A\u03b2(1\u201338), A\u03b2(1\u201340), and A\u03b2(1\u201342) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry. Anal Biochem 419:133\u2013139. https:\/\/doi.org\/10.1016\/j.ab.2011.08.010","journal-title":"Anal Biochem"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.neuroimage.2009.12.059","article-title":"Robust atrophy rate measurement in Alzheimer\u2019s disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection","volume":"50","author":"Leung KK","year":"2010","unstructured":"Leung KK, Clarkson MJ, Bartlett JW et al (2010) Robust atrophy rate measurement in Alzheimer\u2019s disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. NeuroImage 50:516\u2013523. https:\/\/doi.org\/10.1016\/j.neuroimage.2009.12.059","journal-title":"NeuroImage"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang KY","year":"1986","unstructured":"Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13\u201322. https:\/\/doi.org\/10.1093\/biomet\/73.1.13","journal-title":"Biometrika"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/psp4.12759","article-title":"Quantitative systems pharmacology model for Alzheimer\u2019s disease to predict the effect of aducanumab on brain amyloid","volume":"11","author":"Lin L","year":"2022","unstructured":"Lin L, Hua F, Salinas C et al (2022) Quantitative systems pharmacology model for Alzheimer\u2019s disease to predict the effect of aducanumab on brain amyloid. CPT Pharmacometrics Syst Pharmacol 11:362\u2013372. https:\/\/doi.org\/10.1002\/psp4.12759","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0304-4076(85)90158-7","article-title":"Some heteroskedasticity-consistent covariance matrix estimators with improved finite sample properties","volume":"29","author":"MacKinnon JG","year":"1985","unstructured":"MacKinnon JG, White H (1985) Some heteroskedasticity-consistent covariance matrix estimators with improved finite sample properties. J Econom 29:305\u2013325. https:\/\/doi.org\/10.1016\/0304-4076(85)90158-7","journal-title":"J Econom"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13195-026-01995-9","article-title":"\u03b1-Synuclein positivity is associated with decline in brain microstructure in the Alzheimer\u2019s disease spectrum","volume":"18","author":"Mak E","year":"2026","unstructured":"Mak E, Przybelski SA, Reid RI et al (2026) \u03b1-Synuclein positivity is associated with decline in brain microstructure in the Alzheimer\u2019s disease spectrum. Alzheimers Res Ther 18:82. https:\/\/doi.org\/10.1186\/s13195-026-01995-9","journal-title":"Alzheimers Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"495025","DOI":"10.4061\/2011\/495025","article-title":"Cerebrospinal fluid levels of sAPP\u03b1 and sAPP\u03b2 in Lewy body and Alzheimer\u2019s disease: clinical and neurochemical correlates","volume":"2011","author":"Mulugeta E","year":"2011","unstructured":"Mulugeta E, Londos E, Hansson O et al (2011) Cerebrospinal fluid levels of sAPP\u03b1 and sAPP\u03b2 in Lewy body and Alzheimer\u2019s disease: clinical and neurochemical correlates. Int J Alzheimers Dis 2011:495025. https:\/\/doi.org\/10.4061\/2011\/495025","journal-title":"Int J Alzheimers Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2202\/1544-6115.1585","article-title":"Permutation P-values should never be zero: calculating exact P-values when permutations are randomly drawn","volume":"9","author":"Phipson B","year":"2010","unstructured":"Phipson B, Smyth GK (2010) Permutation P-values should never be zero: calculating exact P-values when permutations are randomly drawn. Stat Appl Genet Mol Biol 9. https:\/\/doi.org\/10.2202\/1544-6115.1585. :Article 39","journal-title":"Stat Appl Genet Mol Biol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/psp4.12876","article-title":"Quantitative systems pharmacology model of the amyloid pathway in Alzheimer\u2019s disease: insights into the therapeutic mechanisms of clinical candidates","volume":"12","author":"Ramakrishnan V","year":"2023","unstructured":"Ramakrishnan V, Friedrich C, Witt C et al (2023) Quantitative systems pharmacology model of the amyloid pathway in Alzheimer\u2019s disease: insights into the therapeutic mechanisms of clinical candidates. CPT Pharmacometrics Syst Pharmacol 12:62\u201373. https:\/\/doi.org\/10.1002\/psp4.12876","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e0171925","DOI":"10.1371\/journal.pone.0171925","article-title":"\u03b1-Synuclein increases \u03b2-amyloid secretion by promoting \u03b2-\/\u03b3-secretase processing of APP","volume":"12","author":"Roberts HL","year":"2017","unstructured":"Roberts HL, Schneider BL, Brown DR (2017) \u03b1-Synuclein increases \u03b2-amyloid secretion by promoting \u03b2-\/\u03b3-secretase processing of APP. PLoS ONE 12:e0171925. https:\/\/doi.org\/10.1371\/journal.pone.0171925","journal-title":"PLoS ONE"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"566876","DOI":"10.3389\/fnins.2020.566876","article-title":"Network diffusion modeling explains longitudinal tau PET data","volume":"14","author":"Sch\u00e4fer A","year":"2020","unstructured":"Sch\u00e4fer A, Mormino EC, Kuhl E (2020) Network diffusion modeling explains longitudinal tau PET data. Front Neurosci 14:566876. https:\/\/doi.org\/10.3389\/fnins.2020.566876","journal-title":"Front Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.2517-6161.1974.tb00994.x","article-title":"Cross-validatory choice and assessment of statistical predictions","volume":"36","author":"Stone M","year":"1974","unstructured":"Stone M (1974) Cross-validatory choice and assessment of statistical predictions. J R Stat Soc B 36:111\u2013133. https:\/\/doi.org\/10.1111\/j.2517-6161.1974.tb00994.x","journal-title":"J R Stat Soc B"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1002\/alz.13858","article-title":"A cross-sectional study of \u03b1-synuclein seed amplification assay in Alzheimer\u2019s Disease Neuroimaging Initiative: prevalence and associations with Alzheimer\u2019s disease biomarkers and cognitive function","volume":"20","author":"Tosun D","year":"2024","unstructured":"Tosun D, Hausle Z, Iwaki H et al (2024a) A cross-sectional study of \u03b1-synuclein seed amplification assay in Alzheimer\u2019s Disease Neuroimaging Initiative: prevalence and associations with Alzheimer\u2019s disease biomarkers and cognitive function. Alzheimers Dement 20:5114\u20135131. https:\/\/doi.org\/10.1002\/alz.13858","journal-title":"Alzheimers Dement"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"8444","DOI":"10.1002\/alz.14276","article-title":"Association of CSF \u03b1-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer\u2019s Disease Neuroimaging Initiative study","volume":"20","author":"Tosun D","year":"2024","unstructured":"Tosun D, Hausle Z, Thropp P et al (2024b) Association of CSF \u03b1-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer\u2019s Disease Neuroimaging Initiative study. Alzheimers Dement 20:8444\u20138460. https:\/\/doi.org\/10.1002\/alz.14276","journal-title":"Alzheimers Dement"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13195-019-0537-5","article-title":"Amyloid-\u03b2 peptides in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"11","author":"Steenoven I","year":"2019","unstructured":"van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW (2019) Amyloid-\u03b2 peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimers Res Ther 11:83. https:\/\/doi.org\/10.1186\/s13195-019-0537-5","journal-title":"Alzheimers Res Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","article-title":"Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease","volume":"11","author":"Vogel JW","year":"2020","unstructured":"Vogel JW, Iturria-Medina Y, Strandberg OT et al (2020) Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat Commun 11:2612. https:\/\/doi.org\/10.1038\/s41467-020-15701-2","journal-title":"Nat Commun"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jalz.2010.03.007","article-title":"The Alzheimer\u2019s disease neuroimaging initiative: progress report and future plans","volume":"6","author":"Weiner MW","year":"2010","unstructured":"Weiner MW, Aisen PS, Jack CR Jr et al (2010) The Alzheimer\u2019s disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6:202\u2013211e7. https:\/\/doi.org\/10.1016\/j.jalz.2010.03.007","journal-title":"Alzheimers Dement"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.clinbiochem.2008.04.022","article-title":"Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer\u2019s subjects","volume":"41","author":"Wu G","year":"2008","unstructured":"Wu G, Sankaranarayanan S, Tugusheva K et al (2008) Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer\u2019s subjects. Clin Biochem 41:986\u2013996. https:\/\/doi.org\/10.1016\/j.clinbiochem.2008.04.022","journal-title":"Clin Biochem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/jnr.22618","article-title":"Decrease in brain soluble amyloid precursor protein \u03b2 (sAPP\u03b2) in Alzheimer\u2019s disease cortex","volume":"89","author":"Wu G","year":"2011","unstructured":"Wu G, Sankaranarayanan S, Hsieh SHK, Simon AJ, Savage MJ (2011) Decrease in brain soluble amyloid precursor protein \u03b2 (sAPP\u03b2) in Alzheimer\u2019s disease cortex. J Neurosci Res 89:822\u2013832. https:\/\/doi.org\/10.1002\/jnr.22618","journal-title":"J Neurosci Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41531-026-01382-z","article-title":"Preformed fibrils of \u03b1-synuclein rapidly activate LRRK2 on early endosomes, driving Rab5 phosphorylation and disrupting endolysosomal and synaptic function","volume":"12","author":"Zuo X","year":"2026","unstructured":"Zuo X, Chen Z, Chen XQ et al (2026) Preformed fibrils of \u03b1-synuclein rapidly activate LRRK2 on early endosomes, driving Rab5 phosphorylation and disrupting endolysosomal and synaptic function. NPJ Parkinsons Dis 12:176. https:\/\/doi.org\/10.1038\/s41531-026-01382-z","journal-title":"NPJ Parkinsons Dis"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10731083\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10731083\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T07:41:37Z","timestamp":1788939697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10731083\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":27,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10731083\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,8,27]]},"subtype":"preprint"}}